Clinical Trial Update: R21/MM Dosing, Presentations, and Preservatives [Phase 4]

View source ↗

Summary

This clinical trial update covers Phase 4 dosing for the R21/MM malaria vaccine, along with recent presentations and preservatives used in the formulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria
• Plasmodium Falciparum Malaria

Drugs mentioned

• R21/MM (R21 malaria vaccine with Matrix-M adjuvant)

Snippet

Sponsor: University of Oxford | Conditions: Plasmodium Falciparum Malaria, Malaria | Phase 4 | Status: NOT_YET_RECRUITING